Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...
Financial writer recommends buying ARK Genomic Revolution ETF (ARKG) for potential growth in 2025. Explore more here.
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...
US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...
With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...
Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward ...
Video of Kino Lilly Jr.'s halftime buzzer-beater for Brown men's basketball vs. Dartmouth.